DE60011560T2 - Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert - Google Patents

Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert Download PDF

Info

Publication number
DE60011560T2
DE60011560T2 DE60011560T DE60011560T DE60011560T2 DE 60011560 T2 DE60011560 T2 DE 60011560T2 DE 60011560 T DE60011560 T DE 60011560T DE 60011560 T DE60011560 T DE 60011560T DE 60011560 T2 DE60011560 T2 DE 60011560T2
Authority
DE
Germany
Prior art keywords
flagellin
vaccine
flagella
salmonella
bacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60011560T
Other languages
German (de)
English (en)
Other versions
DE60011560D1 (de
Inventor
Petrus Johannes Maria Nuijten
Maarten Hendrik Witvliet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of DE60011560D1 publication Critical patent/DE60011560D1/de
Application granted granted Critical
Publication of DE60011560T2 publication Critical patent/DE60011560T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60011560T 1999-12-28 2000-12-19 Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert Expired - Lifetime DE60011560T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99204564 1999-12-28
EP99204564 1999-12-28

Publications (2)

Publication Number Publication Date
DE60011560D1 DE60011560D1 (de) 2004-07-22
DE60011560T2 true DE60011560T2 (de) 2005-08-18

Family

ID=8241112

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60011560T Expired - Lifetime DE60011560T2 (de) 1999-12-28 2000-12-19 Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert

Country Status (15)

Country Link
US (2) US20010021386A1 (https=)
EP (1) EP1112747B1 (https=)
JP (1) JP5745731B2 (https=)
AT (1) ATE269104T1 (https=)
AU (1) AU783508B2 (https=)
BR (1) BR0006291B1 (https=)
CA (1) CA2329676A1 (https=)
DE (1) DE60011560T2 (https=)
DK (1) DK1112747T3 (https=)
ES (1) ES2222152T3 (https=)
HU (1) HU226192B1 (https=)
MX (1) MXPA00012796A (https=)
PL (1) PL206377B1 (https=)
PT (1) PT1112747E (https=)
TR (1) TR200401569T4 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4751570B2 (ja) * 2002-09-11 2011-08-17 東レ・ダウコーニング株式会社 オルガノポリシロキサン変性多糖類およびその製造方法
PT2066339E (pt) 2006-09-18 2014-10-31 Texas A & M Univ Sys Composições e métodos de potenciar respostas imunes
US20080260777A1 (en) * 2007-04-19 2008-10-23 Sotomayor Konky Composition and method for controlling intestinal pathogenic organisms
US7935355B2 (en) * 2007-04-19 2011-05-03 Nutritional Health Institute Laboratories, Llc Composition and method for controlling intestinal pathogenic organisms
JP2011502165A (ja) * 2007-10-30 2011-01-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 鞭毛細菌に対する免疫応答を強化する組成物および方法
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
KR101449417B1 (ko) 2012-06-20 2014-10-27 한국외국어대학교 연구산학협력단 살모넬라 엔테리카의 박테리오파아지 및 그 용도
RU2683027C2 (ru) 2012-12-20 2019-03-26 Заклад Бадавчо-Вдроженёвы Осьродка Сальмонельля "Иммуноляб" Сп. З О.О. Поливалентная иммунизирующая и/или терапевтическая композиция для применения при бактериальных инфекциях или пищевом отравлении, в частности сальмонеллёзе, способ получения этой композиции, её применение и вакцина, содержащая эту композицию
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
WO2014164607A1 (en) 2013-03-11 2014-10-09 The Brigham And Women's Hospital, Inc. Vibro-based delivery system and immune suppression
CA2906079C (en) 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
CN111374094B (zh) * 2020-03-02 2022-04-19 扬州大学 驴源马流产沙门氏菌经皮下致非妊娠期小鼠子宫感染模型的建立方法
CN118773056B (zh) * 2024-07-10 2025-07-08 山东省滨州畜牧兽医研究院 一种马流产沙门氏菌灭活疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1109179A (en) * 1964-09-30 1968-04-10 Nat Res Dev Improvements relating to typhoid and paratyphoid vaccines
US4886748A (en) * 1986-03-11 1989-12-12 Shionogi & Co., Ltd. DNA encoding flagellin and vector having the same
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
ATE121782T1 (de) * 1988-05-05 1995-05-15 Praxis Biolog Inc Rekombinante vakzine von flagellin.
JP3436756B2 (ja) * 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
CA2183684C (en) * 1994-02-18 2008-07-15 Richard D. Hansen Inoculation of animals with dried, pelleted biological materials
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6190669B1 (en) * 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen

Also Published As

Publication number Publication date
DE60011560D1 (de) 2004-07-22
HU226192B1 (en) 2008-06-30
EP1112747A1 (en) 2001-07-04
DK1112747T3 (da) 2004-10-25
PL206377B1 (pl) 2010-08-31
JP5745731B2 (ja) 2015-07-08
JP2001186874A (ja) 2001-07-10
PL344851A1 (en) 2001-07-02
EP1112747B1 (en) 2004-06-16
MXPA00012796A (es) 2002-05-23
US20010021386A1 (en) 2001-09-13
AU783508B2 (en) 2005-11-03
HUP0005010A3 (en) 2004-07-28
US20080069843A1 (en) 2008-03-20
PT1112747E (pt) 2004-10-29
AU7245300A (en) 2001-07-05
CA2329676A1 (en) 2001-06-28
ATE269104T1 (de) 2004-07-15
HU0005010D0 (https=) 2001-02-28
HUP0005010A2 (en) 2002-06-29
ES2222152T3 (es) 2005-02-01
BR0006291A (pt) 2001-11-27
BR0006291B1 (pt) 2014-02-18
TR200401569T4 (tr) 2004-07-21

Similar Documents

Publication Publication Date Title
DE60011560T2 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
DE60031974T2 (de) Abgeschwächte Mikroorganismen zur Behandlung von Infektionen
DE3886506T2 (de) Avirulente mikroben und deren verwendungen.
DE69132274T2 (de) Methode der bakteriellen attenuierung und impfstoff
DE69713408T2 (de) Streptococcus equi Impstoff
DE69932425T2 (de) Attenuierte salmonella mutanten, welche das vi-antigen konstant exprimieren
Curtiss III et al. Live oral avirulent Salmonella vaccines
DE69032408T2 (de) Kreuzschützende salmonella impfstoffe
DE69322092T2 (de) Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
DE60112413T2 (de) Ssa inaktivierte salmonella impfstoffe
DE69729839T2 (de) Attenuierter lebender Neospora Impfstoff
DE2836507C2 (https=)
US20080254062A1 (en) Use of an avirulent bordetella mutant as a live vaccine vector
DE69836520T2 (de) Clostridium perfringens Impfstoff
DE69133219T2 (de) Avirulente salmonella mikroben mit einer mutation in dem cdt gen und ihre verwendung
DE60038099T2 (de) Neisseria impfstoffzusammensetzungen und methoden
Roland et al. Expression of Escherichia coli antigens in Salmonella typhimurium as a vaccine to prevent airsacculitis in chickens
DE69631543T2 (de) Immunität gegen pasteurella haemolytica leukotoxin
DE69531186T2 (de) Antibordetella azellulärer Impfstoff
DE2538994A1 (de) Bakterieller impfstoff und verfahren zu seiner herstellung
DE60032293T2 (de) Lebende attenuierte bakterien zur verwendung als impfstoff
EP0642796B1 (de) Salmonella-Lebendimpfstoff
KR20220075555A (ko) 락토바실러스 플란타룸의 플랜타리신을 포함하는 배양액과 반응시킨 살모넬라 갈리나룸 불활화 사균체를 포함하는 가금 티푸스의 예방 또는 치료용 백신 조성물
DE69333402T2 (de) Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1
DE69231724T2 (de) Fischimpfstoff gegen infektion mit aeromonas salmonicida

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: INTERVET INTERNATIONAL B. V., AN BOXMEER, NL